CRNX
Crinetics Pharmaceuticals (CRNX) Stock Valuation
Review Crinetics Pharmaceuticals (CRNX) valuation with server-rendered company data, supporting context and links to related investor research.
- Price to earnings
- 0
- Price to book
- 4.45
- Dividend yield
- 0%
- Return on equity
- 0%
- BTI fair market cap
- $283.29M
- Premium or discount
- 3,062.03%
- Market cap
- $8.96B
Crinetics Pharmaceuticals (CRNX) Stock Valuation research
The Crinetics Pharmaceuticals valuation page presents the available multiples, profitability measures and BTI fair-value context for CRNX. Valuation should be compared with the company's growth, margins, balance sheet and relevant peers rather than judged by one multiple.
A premium may reflect stronger expected growth or quality, while a discount can reflect risk or weak expectations. Neither condition alone establishes that a stock is attractive or unattractive.